What is the latest news on bipolar androgen therapy? Are there any completed or upcoming trials for HSPC (either nm...

According to the National Cancer Institute (NCI) clinical trials database, bipolar androgen therapy is still considered an investigational approach that alternates between high and low testosterone levels in prostate cancer treatment.

The most significant recent evidence comes from ASCO guidelines and presentations, which note:

• The RESTORE trial showed some promise for BAT in metastatic castration-resistant prostate cancer (mCRPC)
• However, for hormone-sensitive prostate cancer (HSPC), whether non-metastatic or metastatic, there are currently no completed Phase 3 trials that support BAT use

According to the NCCN Guidelines (Version 1.2024) for prostate cancer:

• BAT is not currently included in standard treatment algorithms for HSPC
• The guidelines emphasize that testosterone manipulation therapies beyond standard ADT should only be given in the context of clinical trials

Currently active or recruiting trials for BAT in HSPC include:

• NCT05957835: "Bipolar Androgen Therapy in Combination With Darolutamide in Metastatic Hormone Sensitive Prostate Cancer" (Phase 2)

Important note: While this approach is intriguing, both NCCN and ASCO guidelines emphasize that BAT should only be used within clinical trials at this time. I strongly recommend discussing any interest in BAT trials with your oncologist, who can:

1. Evaluate if you might be eligible for any open trials
2. Determine if this experimental approach would be appropriate given your specific situation

Would you like me to provide more specific information about any of the current clinical trials investigating BAT?